Results 111 to 120 of about 38,942 (318)

Ranibizumab plus fufang xueshuantong capsule versus ranibizumab alone for exudative age-related macular degeneration

open access: yesJournal of International Medical Research, 2020
Objective To compare the efficacy of ranibizumab plus fufang xueshuantong capsule (cFXST) with the efficacy of ranibizumab alone in treatment of exudative age-related macular degeneration.
Hai-Tao Pan   +7 more
doaj   +1 more source

Ranibizumab For Diabetic Macular Edema Refractory To Multiple Prior Treatments [PDF]

open access: yes, 2016
Purpose: Diabetic macular edema can be refractory to multiple treatment modalities. Although there have been anecdotal reports of ranibizumab showing efficacy when other modalities provided limited benefit, little has been published on treatment for ...
Ciulla, Lauren   +4 more
core   +2 more sources

Outcomes After Switching to Faricimab in Neovascular Age‐Related Macular Degeneration: Data From the Fight Retinal Blindness! Registry

open access: yesClinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Background We aimed to describe 1‐year outcomes of eyes switched to faricimab from first‐generation vascular endothelial growth factor (VEGF) inhibitors for neovascular age‐related macular degeneration (nAMD) in routine care. Methods Multicentre, observational study of 383 eyes tracked in the Fight Retinal Blindness!
Adrian Hunt   +9 more
wiley   +1 more source

Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study

open access: yesGraefe's Archive for Clinical and Experimental Ophthalmology, 2019
To compare treatment efficacy of anti-VEGF medications following pro re nata (PRN, “as needed”, monthly injections only in case of active disease) or treat and extend (T&E, progressive extension of treatment intervals up to 12 weeks depending on the ...
Michèle Augsburger, G. Sarra, P. Imesch
semanticscholar   +1 more source

Diabetic papillopathy treated with intravitreal ranibizumab

open access: yesInternational Medical Case Reports Journal, 2017
In this report, we present a case of diabetic papillopathy that resolved after a single dose of intravitreal ranibizumab injection. A 50-year-old male presented with painless visual loss in his right eye. His visual acuity was 1/10 in the right eye and 10/10 in the left eye. Anterior segment examination of both eyes was unremarkable.
Deniz Kilic   +3 more
openaire   +5 more sources

Retinal Viral Gene Therapy: Impact of Route of Administration on Serious Adverse Events—A Systematic Review

open access: yesClinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Background To explore the prevalence of serious adverse events (SAEs) associated with retinal viral gene therapy and to examine trends influencing SAE occurrences in human gene therapy surgeries and pre‐clinical animal trials. Methods Literature review was performed to identify peer‐reviewed human and animal studies relevant to viral gene ...
Aubrey Berger   +3 more
wiley   +1 more source

The comparative effectiveness and cost-effectiveness of ranibizumab for neovascular macular degeneration revisited [PDF]

open access: yes, 2017
BACKGROUND: To compare a near decade of follow-up, newer control cohort data, use of both the societal and third party insurer cost perspectives, and integration of unilateral/bilateral therapy on the comparative effectiveness and cost-effectiveness of ...
Adam Turpcu   +4 more
core   +1 more source

Visual Field Changes Over 5 Years in Patients Treated With Panretinal Photocoagulation or Ranibizumab for Proliferative Diabetic Retinopathy.

open access: yesJAMA ophthalmology, 2020
Importance Preservation of peripheral visual field (VF) is considered an advantage for anti-vascular endothelial growth factor agents compared with panretinal photocoagulation (PRP) for treatment of proliferative diabetic retinopathy.
M. Maguire   +10 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy